An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

为解决加拿大婴儿 RSV 预防策略的成本效益及地区差异问题，相关研究人员开展了对 Nirsevimab 和 RSVpreF 的研究。结果表明最佳策略因地区而异，该研究为制定政策提供依据。推荐科研读者阅读，助力深入了解 RSV 预防策略。 在儿童的健康成长过程中，有一种病毒 ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Immunisation with nirsevimab reduced bronchiolitis-related hospitalisations among infants younger than 3 months who visited the emergency department (ED), according to a new study. Nirsevimab also ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.

Visit the CoMMinS study website for full details and results. Title: A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory ...